Market Outlook
By 2032, the U.S. Internet of Medical Things Market is projected to reach approximately USD 162.80 billion, expanding at a CAGR of 19.23% during the forecast period 2027–2032. The market stood at USD 56.65 billion in 2026, following historical values of approximately USD 31.85 billion in 2023, USD 38.40 billion in 2024, and USD 46.50 billion in 2025. Values in this report are expressed in USD billions.
The U.S. Internet of Medical Things industry sits at the convergence of connected clinical medical devices, enterprise digital health infrastructure, cloud data architectures, artificial intelligence-enabled diagnostics, ambulatory telemetry, and hospital workflow automation. Demand is underpinned by the urgent restructuring of American healthcare economics from fee-for-service models toward value-based reimbursement, severe clinical labor shortages across acute and ambulatory nursing environments, and the rapid migration of complex chronic disease management from inpatient hospital wards into decentralized home environments. By 2026, more than 135 million American adults live with one or more chronic conditions, such as hypertension, diabetes, congestive heart failure, and chronic obstructive pulmonary disease, generating over 80% of total national healthcare expenditures.
The clinical profile of the aging U.S. population is establishing permanent device utilization patterns across distributed networks. The cohort of Americans aged 65 and older exceeds 62 million individuals, representing the most device-intensive demographic in medical history. Managing multi-system comorbidities requires clinical-grade, continuously connected hardware capable of streaming high-fidelity physiological waveforms directly into electronic health records without human friction. Devices that once operated as isolated, analog point instruments—such as electrocardiogram monitors, pulse oximeters, volumetric infusion pumps, continuous glucose sensors, and mechanical ventilators—have transformed into intelligent edge-computing nodes governed by bidirectional data transmission and automated clinical decision support.
Hospital enterprise procurement has transitioned from traditional capital equipment purchases to unified, software-enabled clinical ecosystem contracts. Health systems across North America are under severe margin compression, with median hospital operating margins hovering between 1% and 2%. Consequently, hospital chief financial officers, chief medical information officers, and clinical engineering directors refuse to purchase isolated hardware lacking enterprise interoperability. Device vendors must now demonstrate native compatibility with Fast Healthcare Interoperability Resources standards, continuous cybersecurity hygiene complying with federal statutory mandates, and verifiable reductions in 30-day all-cause readmission penalties under the Centers for Medicare and Medicaid Services Hospital Readmissions Reduction Program.
Concurrently, the historical proliferation of uncoordinated digital consumer gadgets is giving way to cleared, prescription-grade medical devices. Clinical acceptance thresholds among American physicians mandate high analytical sensitivity, diagnostic specificity, and continuous background data integrity. Manufacturers are capitalizing on this demand by engineering edge-processing artificial intelligence microchips into biosensors, wearable continuous glucose monitors, smart orthopedic implants, and automated drug delivery systems. These platforms eliminate false-positive alert fatigue, elevate diagnostic accuracy, mitigate adverse drug events, and allow single clinical care teams to oversee thousands of distributed patients simultaneously.
The historical market expanded robustly from 2023 through 2025 as health systems deployed remote physiological monitoring programs following landmark Medicare reimbursement rule expansions, cleared backlogs of surgical telemetry installations, and fortified hospital medical device networks against catastrophic ransomware intrusions. From 2027 onward, market growth will be driven by autonomous closed-loop therapeutic delivery systems, continuous multi-analyte biosensing arrays, private 5G hospital wireless local area networks, algorithmic virtual hospital command centers, and recurring software-as-a-service telemetry analytics contracts spanning acute, post-acute, and residential care settings.
Introduction
The U.S. Internet of Medical Things landscape represents the most technologically advanced and heavily capitalized medtech domain in the world, characterized by the systemic digitization of physical clinical hardware. An American patient navigating the modern healthcare continuum relies on a web of interconnected biometric instruments from admission to long-term post-acute recovery. A patient experiencing acute cardiac decompensation may be stabilized via an intelligent emergency medical services telemetry monitor transmitting 12-lead electrocardiograms to the receiving catheterization laboratory, undergo emergency intervention guided by connected surgical visualization towers, recover in an intensive care unit equipped with centralized biometric monitoring and smart dose-error-reduction infusion systems, and transition home with an adhesive cellular biosensor patch and an automated blood pressure cuff streaming physiological telemetry directly into a hospital-at-home monitoring portal.
This continuous care architecture creates a commercially resilient medtech ecosystem combining upfront capital hardware installations with high-margin, recurring software subscription and consumable sensor revenue streams. Medical devices are no longer static assets depreciated over a seven-year mechanical lifespan; they are dynamic, cloud-connected endpoints that require recurring firmware updates, continuous cybersecurity patching, real-time analytics licensing, and ongoing consumable sensor replenishments. Unlike legacy medical device sales models that terminated upon physical equipment delivery, modern IoMT engagements establish multi-year enterprise relationships that lock health systems into vendor-specific software platforms and proprietary data pipelines.
Federal reimbursement policy has served as the foundational catalyst for this structural evolution. The structural institutionalization of Remote Physiological Monitoring and Remote Therapeutic Monitoring Current Procedural Terminology codes by the Centers for Medicare and Medicaid Services has transformed connected health from an experimental operational cost center into a direct clinical revenue generator for medical practices and health systems. The ability of healthcare organizations to bill for initial device setup, monthly physiological data transmissions, and cumulative clinical staff management time has generated an economic flywheel, incentivizing large health networks to distribute tens of thousands of cellular-enabled blood pressure monitors, weight scales, pulse oximeters, and spirometers to high-risk Medicare and Medicare Advantage beneficiaries.
Clinical operational realities across U.S. healthcare facilities are accelerating this transformation. American hospitals face an unprecedented shortage of registered nurses, respiratory therapists, and specialized medical technologists, with national nursing vacancy rates remaining persistently elevated above historical baselines. This severe workforce contraction makes manual vital sign checks, periodic blood glucose fingersticks, and handwritten fluid intake documentation clinically unsafe and financially unsustainable. Connected medical devices automate data acquisition directly from bedside hardware into electronic health records, eliminating manual data-entry errors, recovering hours of bedside clinical nursing time per shift, and providing automated early warning scoring algorithms that detect patient deterioration hours before clinical arrest occurs.
The market environment is further characterized by the aggressive decentralization of clinical care delivery away from high-cost tertiary hospitals toward ambulatory surgery centers, urgent care clinics, skilled nursing facilities, and residential living spaces. The hospital-at-home care model, supported by temporary and evolving federal regulatory flexibilities, has proven that acute clinical conditions can be treated within domestic environments at lower cost and with superior patient satisfaction, provided the home is equipped with clinical-grade, continuously connected biometric telemetry. This decentralization has catalyzed the design of ultra-miniaturized, low-power, ruggedized medical devices equipped with cellular narrowband IoT and Bluetooth Low Energy transceivers capable of autonomous, plug-and-play operation without patient technical configuration.
From 2027 through 2032, device vendors will compete across comprehensive, end-to-end connected intelligence platforms. Market dominance will no longer be determined by physical hardware ergonomics alone. The industry leaders will be those who seamlessly combine clinical-grade sensor accuracy, zero-trust hardware-level cybersecurity architectures, native electronic health record integration, and edge artificial intelligence that filters raw biometric noise into actionable clinical insights for overburdened healthcare practitioners.
Key Market Drivers: What’s Fueling the U.S. Internet of Medical Things Market Boom?
The foremost primary growth driver is the national demographic aging wave paired with an unprecedented prevalence of multi-system chronic diseases that overwhelm existing hospital bed capacity. The daily transition of more than 10,000 Americans into Medicare eligibility represents a structural demographic shift that guarantees sustained, non-cyclical utilization of medical devices. Conditions such as heart failure, end-stage renal disease, hypertension, chronic obstructive pulmonary disease, and diabetes require continuous, proactive physiological oversight rather than episodic, reactive emergency department interventions. Connected devices, including wearable continuous glucose monitors, implantable cardiac monitors, connected peritoneal dialysis machines, and smart inhalers, establish continuous biometric guardrails around patients, detecting micro-physiological anomalies and prompting targeted pharmaceutical adjustments that prevent catastrophic clinical exacerbations.
A second driver is the aggressive enforcement of federal value-based reimbursement frameworks, alternative payment models, and readmission penalty structures. Programs administered by the Centers for Medicare and Medicaid Services, such as the Hospital Readmissions Reduction Program, the Merit-based Incentive Payment System, and Medicare Shared Savings Program Accountable Care Organizations, penalize hospitals financially for poor post-discharge outcomes while rewarding systems that achieve lower total costs of care. Because hospital readmission for conditions such as heart failure or acute myocardial infarction carries substantial financial forfeitures, health systems invest heavily in post-discharge connected monitoring kits that track patient weights, blood pressure trends, and cardiac rhythms during the vulnerable 30-day post-acute window, directly safeguarding hospital operating margins.
A third driver is the acute, structural clinical staffing crisis plaguing American hospitals and health systems. Registered nurse shortages, allied health departures, and pervasive clinician burnout have forced healthcare facilities to seek labor-saving technological leverage. Traditional manual vital sign collection across inpatient medical-surgical units consumes vast amounts of nursing time and exposes patients to delayed detection of clinical deterioration. Connected bedside multi-parameter monitors, continuous optical biosensor patches, and smart hospital beds equipped with piezoelectric sensor arrays automatically capture and transmit vital signs directly into hospital electronic health records. This automation eliminates documentation bottlenecks, mitigates cognitive load on clinical teams, and mitigates sentinel events through real-time, automated early warning scores.
A fourth driver is the landmark codification and continuous expansion of federal reimbursement codes for remote physiological and therapeutic monitoring. The permanent establishment of dedicated Current Procedural Terminology codes covering device supply, patient education, and monthly clinical management minutes has altered provider financial models. Physicians and integrated delivery networks can generate recurring, predictable fee-for-service revenue while simultaneously driving clinical quality metrics under risk-bearing payer contracts. Commercial payers, including UnitedHealthcare, Humana, Elevance Health, and regional Blue Cross Blue Shield plans, have broadly aligned their coverage policies with Medicare benchmarks, providing uniform economic justification for large-scale device deployment across commercial, Medicare Advantage, and managed Medicaid patient panels.
A fifth driver is the statutory transformation of medical device cybersecurity standards enacted through federal legislative mandates. Following catastrophic ransomware incidents that disrupted regional health systems and forced clinical ambulances to divert, the U.S. Food and Drug Administration received expanded statutory authority under Section 524B of the Federal Food, Drug, and Cosmetic Act to enforce rigorous premarket cybersecurity requirements. Medical device manufacturers must now submit detailed Software Bills of Materials, demonstrate multi-factor authentication controls, maintain verifiable vulnerability disclosure and patching programs, and guarantee device integrity across product lifecycles. This heightened regulatory posture has triggered a massive capital replacement cycle, forcing healthcare systems to decommission obsolete, unpatchable legacy medical hardware in favor of modern, cyber-hardened, zero-trust connected architectures.
A sixth driver is the widespread capital modernization of hospital wireless network infrastructure, characterized by the deployment of Wi-Fi 6, Wi-Fi 6E, and private 5G local area networks across clinical campuses. Legacy medical telemetry systems historically suffered from frequency interference, signal attenuation across shielded radiology suites, and restricted bandwidth that limited real-time waveform transmission. Contemporary private cellular networks and advanced enterprise wireless protocols provide low-latency, deterministic quality of service and dedicated network slicing for life-critical medical telemetry. This enterprise connectivity foundation allows thousands of connected infusion pumps, physiological monitors, mobile clinical communication devices, and surgical robots to communicate simultaneously without packet dropouts or network latency failures.
Finally, consumer-driven expectations for seamless, mobile-first healthcare delivery have compelled healthcare providers to embrace consumer-grade user interfaces backed by clinical-grade diagnostic hardware. The ubiquity of smartphones and ubiquitous high-speed broadband has conditioned American patients to expect digital health interactions that match modern consumer technology. Patients refuse to tolerate cumbersome, tethered medical devices that require complex manual logging or intrusive wiring. Consequently, device manufacturers are engineering sleek, low-profile, water-resistant wearables and companion mobile applications that effortlessly sync diagnostic-grade telemetry to clinical teams, driving superior long-term patient compliance and therapy adherence across diverse socioeconomic populations.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation across the U.S. Internet of Medical Things industry is transforming isolated clinical devices into intelligent, self-orchestrating, edge-computing nodes embedded within enterprise healthcare cloud platforms. The competitive battleground has moved beyond basic physical sensors toward integrated systems combining proprietary biosensing hardware, ultra-low-power microchips, hardware-level cryptographic security, and embedded artificial intelligence algorithms capable of real-time clinical inference.
In ambulatory cardiac telemetry, the industry has transitioned away from bulky, multi-lead Holter monitors requiring skin-irritating lead wires and manual patient diary logs toward ultra-miniaturized, multi-day waterproof adhesive patch biosensors. Modern cardiac patches integrate custom application-specific integrated circuits that continuously analyze single-lead or multi-lead electrocardiogram waveforms directly on the patient’s body. These edge-AI algorithms filter out motion artifacts caused by physical activity and immediately flag malignant arrhythmias, such as paroxysmal atrial fibrillation, ventricular tachycardia, and high-grade atrioventricular blocks. The hardware automatically establishes secure cellular handshakes via embedded eSIM modules, transmitting actionable diagnostic telemetry strips directly to independent diagnostic testing facilities and hospital electronic health record systems without requiring manual patient smartphone pairing.
Continuous glucose monitoring hardware has undergone an engineering evolution characterized by extreme physical miniaturization, extended wear durations, and native connectivity to automated insulin delivery algorithms. Leading continuous glucose biosensors feature fully integrated, disposable one-piece applicators that deploy sub-dermal enzymatic platinum sensors with wear lifespans exceeding 14 to 15 days. Modern biosensors continuously measure interstitial glucose levels every single minute, streaming data via encrypted Bluetooth Low Energy channels directly to smartwatches, smartphones, and automated insulin pump controllers. These devices form closed-loop artificial pancreas systems that autonomously adjust basal insulin delivery and administer corrective micro-boluses in response to predictive glycemic trends, virtually eliminating severe nocturnal hypoglycemia among type 1 and insulin-requiring type 2 diabetes patients.
Intelligent drug delivery platforms and smart infusion systems represent another critical innovation front focused on preventing catastrophic medication errors. Next-generation hospital volumetric and syringe infusion pumps are engineered with wireless enterprise connectivity and dynamic dose error reduction systems. These smart pumps continuously cross-reference real-time intravenous medication orders against hospital electronic medication administration records and computerized physician order entry systems using bidirectional Fast Healthcare Interoperability Resources APIs. Furthermore, connected inhalers and autoinjectors for chronic respiratory and autoimmune conditions incorporate optical and acoustic sensors that evaluate patient inhalation technique, record precise administration timestamps, and provide immediate haptic feedback to patients while alerting clinical care managers to treatment non-compliance.
Implantable medical devices have established an era of continuous, non-invasive home telemetry. Implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, and miniature implantable loop recorders now feature direct Bluetooth connectivity, eliminating the historic requirement for bulky bedside inductive wand monitors that patients frequently forgot to utilize during travel. These smart implants transmit diagnostic telemetry, lead impedance measurements, and battery status updates directly through secure patient mobile applications to cloud monitoring networks. In orthopedics, the commercialization of smart total knee arthroplasty implants featuring embedded micro-sensors, accelerometers, and transceivers allows orthopedic surgeons to remotely track real-time joint range of motion, walking cadence, and gait velocity during postoperative rehabilitation, enabling early detection of implant loosening, infection, or arthrofibrosis before permanent joint failure occurs.
Bedside patient monitoring and virtual nursing infrastructure have advanced through the deployment of multi-modal, non-contact optical and radar biosensors. Next-generation inpatient hospital beds and wall-mounted sensor suites utilize ultra-wideband radar, infrared optical sensors, and piezoelectric mattress transducers to continuously capture respiratory rates, heart rates, micro-movements, and bed-exit trajectories without attaching a single adhesive lead or cuff to the patient. These continuous data streams feed into centralized virtual nursing command centers, where predictive artificial intelligence models calculate real-time clinical deterioration risk scores. This architecture allows a small team of experienced critical care nurses operating in centralized monitoring centers to oversee hundreds of acute medical-surgical beds across regional hospital networks, intervening early during episodes of sepsis, respiratory depression, or impending patient falls.
Segmentation Insights
The U.S. Internet of Medical Things Market is segmented on the basis of component, product type, connectivity technology, clinical application, end user, and geography.
- By Component
The U.S. Internet of Medical Things Market by component is segmented into Hardware and Connected Medical Devices, Software, Middleware and Analytics Platforms, and Services.
Hardware and Connected Medical Devices
Hardware and connected medical devices represent the premier revenue-generating segment, accounting for USD 25.50 billion in 2026, up from USD 14.65 billion in 2023, USD 17.55 billion in 2024, and USD 21.10 billion in 2025. The category is projected to reach USD 70.85 billion by 2032, expanding at an 18.56% CAGR from 2027 to 2032. This extensive category encompasses connected patient monitors, continuous glucose sensors, smart infusion pumps, wearable biosensor patches, connected pulse oximeters, smart spirometers, cellular-enabled blood pressure monitors, implantable cardiac telemetry systems, and digital diagnostic stethoscopes.
Hardware dominance is sustained by the continuous physical deployment of specialized medical sensors across both acute hospital environments and decentralized residential care settings. The physical device serves as the indispensable clinical interface required to transduce biological, chemical, and physical patient signals into digital electronic data streams. Medical hardware must satisfy stringent mechanical, electrical, and biocompatibility safety mandates enforced by the U.S. Food and Drug Administration, demanding substantial capital investment in clinical trials, precision manufacturing, and cleanroom assembly. As healthcare organizations expand continuous monitoring across lower-acuity inpatient beds and establish large-scale remote patient monitoring cohorts, continuous procurement of physical hardware and recurring replacements of single-use, patient-worn biosensors provide the financial foundation of the industry.
Software, Middleware and Analytics Platforms
Software, middleware and analytics platforms accounted for USD 19.95 billion in 2026, following historical figures of USD 10.85 billion in 2023, USD 13.20 billion in 2024, and USD 16.15 billion in 2025. The segment is on track to achieve USD 60.25 billion by 2032, growing at a 20.23% CAGR from 2027 to 2032. Software platforms within this domain include medical device integration engines, cloud-based telemetry dashboards, clinical decision support algorithms, electronic health record interoperability adapters, artificial intelligence-powered predictive analytics tools, and mobile patient engagement applications.
The rapid growth trajectory of this segment reflects the clinical imperative to extract actionable diagnostic insights from vast volumes of raw physiological telemetry. Without intelligent software filtering, billions of continuous data points generated by medical hardware create severe cognitive overload and alarm fatigue for practicing physicians and bedside nurses. Advanced middleware platforms normalize disparate device communication protocols into standardized data models, routing high-priority alerts directly into clinical communication workflows while archiving non-critical trends within hospital electronic records. Software platforms represent high-margin, recurring software-as-a-service revenues that insulate technology vendors from cyclical hardware replacement timelines, driving significant enterprise valuation expansion.
Services
Services generated USD 11.20 billion in 2026, having grown from USD 6.35 billion in 2023, USD 7.65 billion in 2024, and USD 9.25 billion in 2025. This category is anticipated to achieve USD 31.70 billion by 2032, expanding at an 18.93% CAGR from 2027 to 2032. Services encompass medical device cybersecurity management, system integration and deployment, cellular connectivity management, clinical data monitoring services, device onboarding and patient technical support, and regulatory compliance consulting.
The expansion of the services segment is propelled by the sheer operational complexity of maintaining tens of thousands of distributed, life-critical network endpoints across fragmented hospital and home environments. Healthcare provider organizations lack the internal IT staffing and specialized engineering talent required to manage cellular carrier logistics, hardware provisioning, reverse logistics, patient device onboarding, and continuous firmware security patching. Consequently, health systems partner extensively with specialized third-party service providers and device manufacturers who offer managed turnkey solutions. Furthermore, the mandatory enforcement of federal premarket and postmarket medical device cybersecurity requirements has created sustained demand for ongoing penetration testing, threat modeling, and vulnerability monitoring services across commercial medtech fleets.
- By Product Type
The U.S. Internet of Medical Things Market by product type is segmented into Smart Wearable Medical Devices and Biosensors, Implantable Medical Devices and Cardiac Telemetry, Stationary and Bedside Monitoring Platforms, Point-of-Care and Clinical Diagnostic Equipment, and Smart Drug Delivery and Connected Inhalers/Infusion Systems.
Smart Wearable Medical Devices and Biosensors
Smart wearable medical devices and biosensors represent the largest product category, accounting for USD 17.55 billion in 2026, up from historical levels of USD 9.55 billion in 2023, USD 11.65 billion in 2024, and USD 14.25 billion in 2025. The category is projected to reach USD 53.60 billion by 2032, advancing at a 20.44% CAGR from 2027 to 2032. This high-growth category encompasses prescription continuous glucose monitors, multi-parameter wearable patch biosensors, clinical-grade pulse oximetry rings, continuous blood pressure monitoring cuffs, and single-lead and multi-lead ambulatory cardiac telemetry patches.
The dominant revenue position of wearable biosensors is driven by their pivotal role in facilitating continuous chronic disease management and decentralized hospital-at-home acute monitoring. Wearables liberate patients from tethered clinical monitoring, providing freedom of movement while capturing continuous, real-world physiological variations that episodic clinic visits fail to observe. Wearable continuous glucose monitors represent the single highest-volume commercial product in this category, capturing widespread clinical adoption across type 1 and type 2 diabetic populations. Simultaneously, multi-parameter adhesive chest patches tracking continuous respiratory rates, skin temperatures, single-lead electrocardiograms, and body postures are becoming standard post-surgical monitoring tools across acute care discharge pathways.
Implantable Medical Devices and Cardiac Telemetry
Implantable medical devices and cardiac telemetry accounted for USD 13.60 billion in 2026, having expanded from USD 7.95 billion in 2023, USD 9.45 billion in 2024, and USD 11.30 billion in 2025. The segment is on track to achieve USD 36.75 billion by 2032, exhibiting an 18.02% CAGR from 2027 to 2032. Products within this domain include connected pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy systems, implantable loop recorders, connected neurostimulators, and smart orthopedic joint prostheses.
Growth in this segment is anchored in the clinical necessity of continuous, lifelong surveillance for patients suffering from lethal ventricular arrhythmias, severe heart failure, chronic neuropathic pain, and degenerative joint conditions. Implantable cardiac monitors continuously evaluate intracardiac electrograms and fluid accumulation trends within the thoracic cavity, transmitting diagnostic alerts directly to clinical electrophysiology teams when heart failure decompensation is detected. The integration of direct smartphone telemetry interfaces into modern pacemakers and defibrillators has permanently displaced legacy tabletop transceivers, substantially elevating patient transmission compliance, accelerating clinical interventions during arrhythmic emergencies, and reducing emergency department utilization.
Stationary and Bedside Monitoring Platforms
Stationary and bedside monitoring platforms generated USD 10.15 billion in 2026, following historical revenues of USD 6.05 billion in 2023, USD 7.15 billion in 2024, and USD 8.50 billion in 2025. This category is projected to achieve USD 26.80 billion by 2032, expanding at a 17.56% CAGR from 2027 to 2032. Systems in this classification encompass high-acuity intensive care unit patient monitors, operating room multi-parameter workstations, centralized telemetry nursing displays, non-contact optical inpatient surveillance beds, and stationary hemodialysis monitoring consoles.
Stationary monitors represent the high-reliability backbone of acute clinical inpatient care. In intensive care units, emergency departments, and progressive care step-down units, these platforms continuously aggregate invasive arterial blood pressures, central venous pressures, multi-lead electrocardiography, end-tidal carbon dioxide, continuous cardiac output, and core body temperatures. Modern bedside monitoring systems feature modular acquisition units, large-format high-definition touch interfaces, and integrated edge processing capable of running sophisticated clinical deterioration algorithms. These systems continuously feed normalized physiological waveforms into hospital electronic health records and central nursing stations, ensuring that critical care clinicians maintain immediate situational awareness across full hospital units.
Point-of-Care and Clinical Diagnostic Equipment
Point-of-care and clinical diagnostic equipment accounted for USD 8.15 billion in 2026, up from USD 4.45 billion in 2023, USD 5.40 billion in 2024, and USD 6.60 billion in 2025. The category is projected to reach USD 24.45 billion by 2032, demonstrating a 20.08% CAGR from 2027 to 2032. This segment comprises connected handheld ultrasound scanners, digital stethoscopes, point-of-care blood chemistry and blood gas analyzers, connected coagulation meters, smart otoscopes, and mobile clinical hematology platforms.
The commercial velocity of point-of-care diagnostic devices stems from the decentralization of clinical diagnostics toward outpatient clinics, urgent care centers, and ambulatory triage suites. Connected handheld ultrasound probes that plug directly into mobile tablets allow emergency room physicians and outpatient internists to evaluate cardiac function, detect abdominal hemorrhage, and guide vascular access at the point of presentation. Digital stethoscopes equipped with active acoustic noise cancellation, wireless Bluetooth audio streaming, and integrated electrocardiogram sensors allow clinicians to record, visualize, and analyze phonocardiograms, using automated machine learning algorithms to detect structural heart murmurs and valvular abnormalities during routine primary care examinations.
Smart Drug Delivery and Connected Inhalers/Infusion Systems
Smart drug delivery and connected inhalers and infusion systems accounted for USD 7.20 billion in 2026, having grown from USD 3.85 billion in 2023, USD 4.75 billion in 2024, and USD 5.85 billion in 2025. By 2032, the category is projected to reach USD 21.20 billion, reflecting a 19.72% CAGR from 2027 to 2032. Products include enterprise wireless smart volumetric and syringe infusion pumps, automated insulin delivery pumps, connected dry powder and metered-dose inhalers, smart autoinjectors, and wireless ambulatory elastomeric infusion devices.
Demand is catalyzed by the critical imperative to mitigate preventable medication errors and monitor patient therapy adherence in both acute inpatient care and outpatient chronic therapies. In hospital settings, connected smart infusion pumps utilize enterprise wireless networks to download standardized hospital drug libraries with strict hard and soft dosage limits, dramatically reducing catastrophic drug dosing miscalculations. In outpatient respiratory and immunology care, connected inhalers and electronic autoinjectors automatically capture the time, volume, and physiological inhalation pressure of drug administration, streaming real-world adherence data to treating pulmonologists and health plan clinical care coordinators to optimize therapeutic regimens and prevent costly emergency department admissions.
- By Connectivity Technology
The U.S. Internet of Medical Things Market by connectivity technology is segmented into Cellular and Narrowband IoT (NB-IoT/LTE-M/5G), Wireless Personal Area Networks (Bluetooth Low Energy/Zigbee), Wi-Fi and Local Area Wireless Systems, Near Field Communication and Radio Frequency Identification (RFID), and Satellite and Hybrid Wide Area Telemetry.
Cellular and Narrowband IoT (NB-IoT / LTE-M / 5G)
Cellular and narrowband IoT represents the largest and fastest-expanding connectivity segment, accounting for USD 20.25 billion in 2026, up from historical levels of USD 10.80 billion in 2023, USD 13.25 billion in 2024, and USD 16.30 billion in 2025. The category is projected to reach USD 61.95 billion by 2032, advancing at a 20.47% CAGR from 2027 to 2032. This technology segment encompasses embedded 4G LTE, 5G standalone and non-standalone modules, LTE-M (Long Term Evolution for Machines), and Narrowband IoT modems integrated directly into remote physiological monitoring devices.
Cellular dominance in remote patient monitoring is anchored in its unmatched out-of-the-box simplicity, high network reliability, and complete elimination of patient-side setup friction. Older patient demographics, who represent the primary consumers of remote chronic disease monitoring, frequently lack home Wi-Fi networks or struggle with complex Bluetooth smartphone pairing procedures. Cellular-enabled medical devices feature factory-integrated global or national eSIM cards that establish automatic, encrypted connections with commercial cellular towers immediately upon device activation. Furthermore, the deployment of private 5G networks across large academic medical campuses provides dedicated, ultra-low latency, and highly secure wireless spectrum for hospital-wide clinical communications, mobile robotic surgical systems, and mission-critical patient telemetry.
Wireless Personal Area Networks (Bluetooth Low Energy / Zigbee)
Wireless personal area networks, led primarily by Bluetooth Low Energy, accounted for USD 17.20 billion in 2026, following historical figures of USD 9.85 billion in 2023, USD 11.85 billion in 2024, and USD 14.25 billion in 2025. The segment is on track to achieve USD 47.85 billion by 2032, expanding at an 18.60% CAGR from 2027 to 2032. This category includes Bluetooth 5.0 through 5.4 protocols and Zigbee wireless mesh networks utilized in patient-worn biosensors, continuous glucose monitors, digital thermometers, smart insulin pens, and wearable pulse oximeters.
Bluetooth Low Energy represents the standard short-range wireless standard for personal healthcare devices due to its ultra-low power consumption profile and universal hardware compatibility with commercial smartphones, tablets, and smartwatches. Medical-grade BLE chips operate for months or even years on miniature coin-cell batteries, enabling the engineering of ultra-compact, featherweight adhesive patches and continuous glucose biosensors that patients can wear comfortably during daily activities, exercise, and sleep. BLE transceivers continuously sync high-resolution biometric data packets to companion mobile gateway applications, which then handle secure data encryption and cloud backhaul transmission to enterprise electronic health records.
Wi-Fi and Local Area Wireless Systems
Wi-Fi and local area wireless systems accounted for USD 11.85 billion in 2026, having expanded from USD 7.00 billion in 2023, USD 8.30 billion in 2024, and USD 9.90 billion in 2025. By 2032, the category is projected to reach USD 31.80 billion, exhibiting a 17.89% CAGR from 2027 to 2032. Products utilizing this technology include enterprise Wi-Fi 6 and Wi-Fi 6E connected bedside patient monitors, mobile tablet workstations, stationary infusion pump fleets, connected medical imaging carts, and automated clinical laboratory diagnostic instruments.
Enterprise clinical Wi-Fi networks provide the high-bandwidth backbone required to transmit high-definition medical imaging, multi-channel real-time physiological waveforms, and bidirectional electronic health record documentation within hospital environments. The adoption of Wi-Fi 6 and Wi-Fi 6E standards operating in the 6 GHz spectrum band has resolved historic hospital network congestion issues, providing dedicated, interference-free channels for mission-critical medical hardware. Enterprise Wi-Fi protocols support robust WPA3-Enterprise cryptographic security standards, allowing hospital clinical engineering and IT departments to isolate medical device fleets into dedicated, firewalled virtual local area networks that protect connected clinical hardware from external enterprise cyber intrusions.
Near Field Communication (NFC) and Radio Frequency Identification (RFID)
Near field communication and radio frequency identification accounted for USD 4.70 billion in 2026, up from USD 2.85 billion in 2023, USD 3.35 billion in 2024, and USD 3.95 billion in 2025. The segment is projected to reach USD 12.45 billion by 2032, demonstrating a 17.62% CAGR from 2027 to 2032. Applications include real-time location systems for hospital asset tracking, surgical sponge and instrument tracking, automated patient identification wristbands, smart pharmaceutical inventory cabinets, and contactless sensor activation interfaces.
NFC and RFID technologies provide high-efficiency physical identification, authentication, and inventory tracking across complex clinical environments. High-frequency passive RFID tags integrated into hospital assets—such as portable ventilators, mobile ultrasound units, and specialized surgical trays—allow hospital clinical engineering teams to instantly locate critical equipment across sprawling multi-building hospital complexes, eliminating wasted clinical search time and optimizing equipment utilization rates. Near field communication enables instantaneous, tap-to-pair authentication between wearable diagnostic sensors and mobile reader devices, while ensuring tamper-proof verification of pharmaceuticals within automated medication dispensing cabinets.
Satellite and Hybrid Wide Area Telemetry
Satellite and hybrid wide area telemetry generated USD 2.65 billion in 2026, having grown from USD 1.35 billion in 2023, USD 1.65 billion in 2024, and USD 2.10 billion in 2025. The segment is on track to achieve USD 8.75 billion by 2032, reflecting a 22.03% CAGR from 2027 to 2032. This specialized, high-growth connectivity category includes low Earth orbit satellite communication modules, Wireless Medical Telemetry Service proprietary RF bands, and multi-bearer hybrid transceivers deployed in air medical transport services, remote rural disaster relief vehicles, offshore clinical operations, and inter-hospital ground critical care ambulances.
The rapid expansion of hybrid satellite and wide-area telemetry reflects the clinical necessity of maintaining uninterrupted biometric surveillance during critical patient transit across vast geographic distances lacking dependable terrestrial cellular coverage. Fixed-wing and rotary emergency medical air transport teams utilize hybrid satellite-cellular telemetry platforms to transmit continuous multi-lead ECGs, invasive arterial waveforms, and automated ventilator metrics from remote trauma scenes directly to tertiary trauma centers. As low Earth orbit satellite constellations expand commercial availability, medtech manufacturers are integrating direct-to-satellite messaging chips into ambulatory emergency beacons and remote critical care monitors, ensuring complete telemetry continuity across every square mile of the American landmass.
- By Clinical Application
The U.S. Internet of Medical Things Market by clinical application is segmented into Remote Patient Monitoring and Chronic Disease Management, Patient Telemetry and Intensive/Critical Care, Medication Management and Adherence Tracking, Clinical Workflow Automation and Asset Tracking, Surgical and Interventional Navigation/Robotics, and Emergency Response and Trauma Telemetry.
Remote Patient Monitoring (RPM) and Chronic Disease Management
Remote patient monitoring and chronic disease management represents the premier clinical application, accounting for USD 20.65 billion in 2026, following historical figures of USD 11.15 billion in 2023, USD 13.65 billion in 2024, and USD 16.75 billion in 2025. This application is projected to reach USD 63.15 billion by 2032, advancing at a 20.48% CAGR from 2027 to 2032. Clinical conditions managed under this domain encompass congestive heart failure, hypertension, type 1 and type 2 diabetes, chronic kidney disease, asthma, and chronic obstructive pulmonary disease.
The commercial supremacy of remote chronic disease monitoring is anchored in the immense macroeconomic burden of chronic illness on the American healthcare system. Managing chronic conditions through continuous outpatient telemetry prevents acute decompensation episodes that necessitate emergency room visits and multi-day inpatient hospitalizations. Remote patient monitoring programs equip patients with connected blood pressure cuffs, continuous glucose monitors, weight scales, and pulse oximeters that continuously stream physiological measurements to clinical care managers. Machine learning algorithms analyze these data streams in real time, detecting micro-trends—such as a three-pound weight gain over 48 hours in a heart failure patient—prompting immediate diuretic adjustments that keep the patient stable at home and prevent readmissions.
Patient Telemetry and Intensive/Critical Care
Patient telemetry and intensive and critical care accounted for USD 12.55 billion in 2026, up from USD 7.35 billion in 2023, USD 8.75 billion in 2024, and USD 10.45 billion in 2025. The category is projected to achieve USD 33.90 billion by 2032, expanding at an 18.01% CAGR from 2027 to 2032. Applications include continuous electrocardiographic surveillance, central venous pressure telemetry, continuous arterial line monitoring, intracranial pressure tracking, and automated pulse oximetry monitoring across intensive care units, step-down units, and post-anesthesia care suites.
Continuous inpatient telemetry represents the primary defense against unexpected clinical deterioration, cardiac arrest, and sepsis across acute hospital environments. Traditional telemetry required patients to carry cumbersome transmitters that communicated over narrow radiofrequency bands to dedicated monitoring rooms. Modern patient telemetry systems leverage enterprise Wi-Fi and Bluetooth mesh networks, enabling untethered, continuous surveillance throughout the hospital. These systems integrate intelligent alarm management software that filters benign motion artifacts and false alarms, reducing alarm fatigue for bedside nurses while accelerating response times during life-threatening events such as ventricular fibrillation or acute respiratory depression.
Medication Management and Adherence Tracking
Medication management and adherence tracking generated USD 8.15 billion in 2026, having grown from USD 4.45 billion in 2023, USD 5.40 billion in 2024, and USD 6.60 billion in 2025. The segment is on track to achieve USD 24.25 billion by 2032, exhibiting a 19.92% CAGR from 2027 to 2032. Products within this scope encompass connected smart pill dispensers, digital smart blister packs, smart insulin pens, connected inhaler sensors, electronic autoinjectors, and automated hospital medication dispensing cabinets.
Medication non-adherence represents a massive clinical and economic failure mode in the United States, driving over USD 100 billion in avoidable annual healthcare expenditures. Connected medication devices convert passive pharmaceutical regimens into active, verifiable data loops. Smart pillboxes and connected inhalers automatically record the precise moment a medication compartment is accessed or an aerosol dose is actuated. If a patient misses a scheduled medication dose, automated cellular notifications prompt the patient via SMS or voice call, while persistent non-compliance triggers an alert on the dashboard of an assigned clinical care coordinator, enabling timely intervention before clinical disease exacerbation occurs.
Clinical Workflow Automation and Asset Tracking
Clinical workflow automation and asset tracking accounted for USD 6.60 billion in 2026, following historical revenues of USD 3.80 billion in 2023, USD 4.55 billion in 2024, and USD 5.45 billion in 2025. The segment is projected to reach USD 18.25 billion by 2032, expanding at an 18.47% CAGR from 2027 to 2032. This domain includes real-time location systems using Bluetooth Low Energy beacons, ultra-wideband tags, and Wi-Fi triangulation to track clinical staff, patients, mobile medical hardware, temperature-sensitive pharmaceutical inventories, and surgical instrument trays.
Hospital operational efficiency depends on the seamless coordination of physical assets and clinical staff across expansive physical facilities. Clinical personnel spend significant portions of their shifts searching for mobile capital devices such as infusion pumps, bladder scanners, and specialized transport wheelchairs. Real-time location systems integrate with hospital enterprise resource planning software to provide real-time maps of equipment availability, automated preventative maintenance scheduling, and geofenced loss prevention. Furthermore, RFID-enabled environmental monitoring sensors continuously log temperatures inside cryogenic freezers and blood bank storage units, automatically alerting facilities management if temperatures deviate from strict federal regulatory storage guidelines.
Surgical and Interventional Navigation / Robotics
Surgical and interventional navigation and robotics accounted for USD 5.55 billion in 2026, up from USD 3.10 billion in 2023, USD 3.75 billion in 2024, and USD 4.55 billion in 2025. The segment is on track to achieve USD 15.55 billion by 2032, reflecting an 18.73% CAGR from 2027 to 2032. This application comprises connected robotic-assisted surgical consoles, intraoperative surgical navigation systems, connected orthopedic cutting guides, digital operating room integration suites, and cloud-enabled tele-mentoring platforms.
The integration of the Internet of Medical Things into the operating room has transformed surgical intervention from an isolated mechanical procedure into a connected, data-rich clinical discipline. Connected surgical robots stream millions of telemetry points per procedure, recording robotic arm kinematics, instrument articulation forces, tissue impedance variations, and video feeds directly into secure clinical cloud databases. These data streams feed machine learning algorithms that provide predictive surgical guidance, automate procedural documentation, and enable expert surgical specialists to tele-mentor community surgeons across encrypted, low-latency network connections, elevating surgical precision and standardizing procedural outcomes.
Emergency Response and Trauma Telemetry
Emergency response and trauma telemetry generated USD 3.15 billion in 2026, having expanded from USD 2.00 billion in 2023, USD 2.30 billion in 2024, and USD 2.70 billion in 2025. By 2032, the category is projected to reach USD 7.70 billion, growing at a 16.06% CAGR from 2027 to 2032. Applications include ruggedized pre-hospital emergency multi-parameter monitors, cloud-connected automated external defibrillators, mobile stroke unit diagnostic telemetry, and connected trauma resuscitation carts.
In emergency medicine, time to definitive clinical intervention determines patient survival across stroke, STEMI, and traumatic hemorrhage emergencies. Connected pre-hospital telemetry devices bridge the critical communication gap between field emergency medical technicians and receiving hospital emergency trauma teams. Mobile diagnostic monitors continuously transmit 12-lead ECGs, ultrasound video clips, and patient vital signs directly to attending trauma surgeons and interventional cardiologists while the ambulance is in transit. This real-time situational awareness allows hospital catheterization teams and trauma suites to be fully prepped and waiting prior to patient arrival, dramatically reducing door-to-balloon and door-to-needle times and saving vital myocardial and cerebral tissue.
- By End User
The U.S. Internet of Medical Things Market by end user is segmented into Hospitals and Health Systems, Home Healthcare and Long-Term Care Settings, Ambulatory Surgery Centers and Outpatient Clinics, Specialized Clinical Research Centers and Decentralized Trials, and Diagnostic Laboratories and Imaging Centers.
Hospitals and Health Systems
Hospitals and health systems represent the largest end-user category, accounting for USD 28.25 billion in 2026, up from USD 16.25 billion in 2023, USD 19.45 billion in 2024, and USD 23.35 billion in 2025. The category is projected to reach USD 78.15 billion by 2032, expanding at an 18.48% CAGR from 2027 to 2032. This segment comprises tertiary academic medical centers, integrated delivery networks, regional non-profit hospital systems, and public safety-net healthcare institutions.
Hospitals and integrated health systems represent the primary capital investors in connected medical device infrastructure due to their substantial capital expenditure budgets, high clinical acuity levels, and complex regulatory compliance obligations. Health systems manage fleets consisting of tens of thousands of connected devices, including bedside multi-parameter monitors, smart infusion pumps, connected ventilators, and enterprise asset tracking tags. Institutional procurement behavior in this segment is governed by centralized purchasing committees comprising chief information officers, chief medical officers, biomedical engineering directors, and supply chain executives. These enterprise buyers mandate robust electronic health record interoperability, comprehensive cybersecurity guarantees, and measurable reductions in clinical labor costs and clinical adverse events.
Home Healthcare and Long-Term Care Settings
Home healthcare and long-term care settings accounted for USD 14.55 billion in 2026, following historical figures of USD 7.65 billion in 2023, USD 9.45 billion in 2024, and USD 11.70 billion in 2025. The segment is on track to achieve USD 45.60 billion by 2032, reflecting a 20.98% CAGR from 2027 to 2032. This segment encompasses certified home health agencies, skilled nursing facilities, assisted living communities, residential hospice care providers, and specialized hospital-at-home operating programs.
This classification represents the fastest-growing end-user segment within the American market, driven by the economic imperative to manage high-need, high-cost patients outside of expensive hospital inpatient environments. Certified home health agencies and post-acute skilled nursing facilities deploy fleets of cellular-connected remote patient monitoring kits to manage post-surgical recovery, wound healing, and chronic cardiopulmonary disease. The operational success of the hospital-at-home clinical care model relies directly on continuous biometric monitoring platforms, smart infusion pumps, and portable oxygen concentrators deployed directly into private residential living spaces, enabling acute-level clinical care delivery at a fraction of standard inpatient operational costs.
Ambulatory Surgery Centers and Outpatient Clinics
Ambulatory surgery centers and outpatient clinics generated USD 7.85 billion in 2026, having grown from USD 4.45 billion in 2023, USD 5.35 billion in 2024, and USD 6.45 billion in 2025. The category is projected to reach USD 22.50 billion by 2032, expanding at a 19.19% CAGR from 2027 to 2032. Facilities in this domain include physician-owned surgical centers, multi-specialty physician practices, urgent care clinic networks, and outpatient dialysis centers.
The migration of complex surgical procedures—including total joint replacements, spinal fusions, and advanced cardiac catheterizations—from inpatient hospital operating rooms into outpatient ambulatory surgery centers has driven aggressive procurement of connected clinical technology. Ambulatory surgery centers operate with lean clinical staffing and rapid surgical turnaround schedules, placing a premium on connected clinical hardware that automates procedural documentation, monitors post-operative anesthesia recovery, and facilitates seamless post-discharge patient tracking. Outpatient facilities prioritize compact, highly interoperable devices that integrate directly with cloud-based electronic health record platforms and billing clearinghouses without requiring extensive on-site IT infrastructure.
Specialized Clinical Research Centers and Decentralized Trials
Specialized clinical research centers and decentralized clinical trials accounted for USD 3.70 billion in 2026, up from USD 2.15 billion in 2023, USD 2.55 billion in 2024, and USD 3.05 billion in 2025. The category is projected to reach USD 10.45 billion by 2032, demonstrating an 18.89% CAGR from 2027 to 2032. This segment encompasses contract research organizations, pharmaceutical biotechnology sponsors, academic clinical trials offices, and decentralized trial technology platforms.
The structural transformation of biopharmaceutical clinical development toward decentralized and hybrid trial designs has generated massive demand for clinical-grade connected medical devices. Clinical trial protocols increasingly require continuous, objective biometric endpoints rather than intermittent, subjective clinic assessments. Pharmaceutical sponsors equip clinical trial participants with wearable continuous glucose monitors, digital spirometers, medical-grade actigraphy patches, and connected blood pressure monitors to collect continuous, real-world efficacy and safety data. Connected devices expand patient recruitment demographics, eliminate geographic trial participation barriers, improve participant retention rates, and compress drug development timelines through real-time safety surveillance.
Diagnostic Laboratories and Imaging Centers
Diagnostic laboratories and imaging centers accounted for USD 2.30 billion in 2026, following historical levels of USD 1.35 billion in 2023, USD 1.60 billion in 2024, and USD 1.95 billion in 2025. By 2032, the category is projected to reach USD 6.10 billion, exhibiting a 17.65% CAGR from 2027 to 2032. Facilities include independent clinical reference laboratories, outpatient diagnostic radiology networks, and independent diagnostic testing facilities.
Diagnostic facilities rely heavily on connected devices to automate specimen processing, track high-volume patient diagnostic telemetry, and optimize expensive imaging asset utilization. Independent diagnostic testing facilities represent critical hubs that continuously ingest, process, and analyze millions of days of ambulatory electrocardiographic monitoring, continuous glucose telemetry, and home sleep apnea tests streamed from connected devices across the nation. Connected automated laboratory analyzers utilize bidirectional cloud interfaces to transmit diagnostic laboratory results directly into treating physician EHR portals minutes after specimen analysis, accelerating clinical decision-making and optimizing outpatient diagnostic workflows.
Regional Insights: Where the Market is Growing Fastest
The U.S. Internet of Medical Things Market is geographically segmented into four primary commercial regions: the South, the West, the Midwest, and the Northeast. Regional market performance is governed by underlying structural dynamics, including demographic concentration, chronic disease disease burden, hospital consolidation velocity, state-level telehealth and remote monitoring reimbursement parity statutes, broadband and cellular telecommunications infrastructure, and the distribution of premier academic medical centers and health systems.
South
The South represents the largest overall commercial regional market for the Internet of Medical Things in the United States, generating USD 20.25 billion in 2026, up from historical levels of USD 11.15 billion in 2023, USD 13.55 billion in 2024, and USD 16.50 billion in 2025. The Southern regional market is projected to reach USD 59.45 billion by 2032, expanding at a 19.66% CAGR from 2027 to 2032. The South’s commercial revenue leadership is anchored by its vast population concentration, nation-leading rates of cardiovascular disease, hypertension, and type 2 diabetes, rapid demographic in-migration, and an extensive network of large for-profit and non-profit hospital health systems aggressively scaling remote patient monitoring to manage high-risk patient cohorts.
Texas represents the dominant economic engine within the Southern IoMT landscape, supported by a massive population exceeding 30 million residents, extensive urban healthcare corridors, and profound rural healthcare delivery challenges. The Texas Medical Center in Houston, recognized as the largest medical complex in the world, alongside premier healthcare systems including Houston Methodist, Memorial Hermann, Baylor Scott & White Health, and UT Southwestern Medical Center in Dallas, commands substantial enterprise budgets for connected medical device procurement. Texas healthcare institutions invest heavily in enterprise smart infusion pump fleets, connected ICU telemetry platforms, and hospital-wide real-time asset tracking networks to optimize complex inpatient workflows. Outside major metropolitan centers, rural hospital closures across vast West Texas and East Texas expanses have compelled regional healthcare networks to deploy large-scale cellular-enabled remote patient monitoring programs, distributing connected blood pressure cuffs and weight scales to manage chronic heart failure and diabetic populations across underserved counties. Furthermore, Texas boasts a thriving medical device and software innovation corridor across Austin and Dallas, supported by state initiatives that incentivize the development of AI-enabled biometric telemetry platforms.
Florida represents the second-largest state market within the South, distinguished by its unique demographic concentration of over 4.6 million senior citizens aged 65 and older. Metros such as Miami, Fort Lauderdale, Tampa-St. Petersburg, Orlando, and Jacksonville host dense concentrations of health systems, Medicare Advantage health plans, and certified home health agencies. Florida’s high Medicare Advantage penetration rate, exceeding 58% of eligible beneficiaries, creates an environment where health insurance plans directly incentivize healthcare systems to deploy connected remote physiological monitoring to prevent costly inpatient admissions for congestive heart failure and chronic obstructive pulmonary disease. Major health networks, including AdventHealth, Baptist Health South Florida, Tampa General Hospital, and the Mayo Clinic campus in Jacksonville, maintain centralized virtual command centers that ingest continuous biometric telemetry from thousands of post-acute patients. Furthermore, Florida’s susceptibility to extreme weather events and severe hurricanes has prompted regional health networks to invest in ruggedized, battery-backed cellular medical telemetry systems that ensure clinical monitoring continuity during municipal power and telecommunication disruptions.
North Carolina and Georgia represent dynamic, technology-driven healthcare hubs characterized by dense academic medicine networks and expansive healthcare system consolidations. In North Carolina, the Research Triangle region, encompassing Duke Health, UNC Health, and WakeMed, alongside Charlotte-based Atrium Health (part of Advocate Health), represents one of the most innovative digital health corridors in the United States. These institutions have pioneered large-scale virtual hospital programs, deploying wearable patch biosensors and cellular continuous glucose monitors to oversee thousands of patients in hospital-at-home pathways. North Carolina’s progressive state regulatory policies regarding medical device integration and digital health pilots have attracted substantial venture and corporate medtech capital. Georgia, anchored by the sprawling Atlanta metropolitan region and healthcare giants such as Emory Healthcare, Piedmont Healthcare, and Wellstar Health System, demonstrates aggressive procurement of connected patient telemetry and smart drug delivery platforms. Atlanta’s status as a major telecommunications and software hub provides an ideal testing environment for private 5G hospital wireless deployments and advanced medical IoT cybersecurity operations.
Tennessee, Virginia, and the broader Gulf Coast states—encompassing Louisiana, Alabama, and Mississippi—sustain substantial demand across acute care and remote chronic disease monitoring. Tennessee, recognized as the operational center of the American for-profit hospital industry, hosts corporate headquarters for major hospital operators, including HCA Healthcare and Community Health Systems in Nashville. These corporate hospital systems mandate enterprise-wide medical device standardizations, executing multi-million-dollar national procurement contracts for smart infusion systems, connected bedside monitors, and IoMT cybersecurity platforms across hundreds of affiliated hospital facilities nationwide. Virginia features a highly affluent, digitally integrated healthcare corridor across Northern Virginia and the Richmond metropolitan area, where health systems such as Inova Health System and VCU Health aggressively procure cloud-connected surgical navigation and patient telemetry systems. In contrast, Alabama, Mississippi, and Louisiana exhibit some of the highest per-capita rates of end-stage renal disease, stroke, and cardiovascular mortality in the nation, driving clinical deployment of connected peritoneal dialysis machines, continuous ambulatory cardiac patches, and cellular-enabled hypertension management devices to mitigate severe regional health disparities.
The commercial challenge across the South centers on addressing significant digital equity divides between affluent, digitally connected urban medical centers and historically under-resourced rural hospital networks. While urban tertiary facilities rapidly implement private 5G networks and 4K surgical video streaming, rural clinics frequently navigate spotty broadband coverage and limited local IT engineering support. Manufacturers that engineer medical devices with multi-carrier cellular fallback, ultra-low-power consumption profiles, and automated zero-configuration setup capture decisive competitive advantages across this expansive territory.
West
The West represents the fastest-growing regional market for the Internet of Medical Things through 2032, accounting for USD 16.35 billion in 2026, following historical revenues of USD 8.90 billion in 2023, USD 10.85 billion in 2024, and USD 13.25 billion in 2025. The Western market is projected to reach USD 48.70 billion by 2032, demonstrating a 19.95% CAGR from 2027 to 2032. The region’s exceptional growth velocity is propelled by early clinical technology adoption, nation-leading venture capital and private equity investment in digital health, progressive state-level telehealth and data privacy policies, and the dense concentration of globally preeminent medtech and software engineering conglomerates.
California represents the undisputed economic powerhouse of the Western region and the single largest state market for the Internet of Medical Things in the nation. Supported by a population of nearly 39 million residents and an annual healthcare expenditure exceeding USD 450 billion, California serves as the primary global incubator and commercial proving ground for connected medical technology. The San Francisco Bay Area, Silicon Valley, Greater Los Angeles, Orange County, and San Diego support hundreds of specialized medtech firms, semiconductor designers, and digital health software developers. Elite healthcare systems, including Stanford Health Care, Cedars-Sinai Medical Center, Kaiser Permanente, UCLA Health, and the University of California Health system, operate some of the most technologically advanced medical facilities in the world. California hospitals are rapid adopters of AI-enabled edge biosensors, continuous non-contact patient surveillance beds, connected surgical robotic suites, and cloud-integrated medication delivery systems. Furthermore, California’s stringent data privacy regulatory environment, governed by the California Consumer Privacy Act and California Confidentiality of Medical Information Act, compels device manufacturers to engineer enterprise-grade cryptographic security, zero-trust hardware access controls, and transparent data audit logging directly into their connected device architectures.
Washington and Oregon represent mature, highly innovative healthcare markets characterized by extensive health IT integration and high consumer digital health literacy. The Seattle metropolitan area, anchored by Providence Health, UW Medicine, and Virginia Mason Franciscan Health, operates as a nexus where enterprise cloud computing giants and clinical medicine intersect. The presence of global cloud infrastructure titans in the region has accelerated the development of cloud-native healthcare data lakes, FHIR-compliant medical device ingestion pipelines, and predictive patient monitoring algorithms. Healthcare institutions across Washington and Oregon actively deploy wearable continuous biosensors and cellular remote patient monitoring devices across extensive outpatient primary care networks. Oregon, known for its progressive coordinated care organizations and value-based Medicaid payment models, demonstrates high institutional demand for connected chronic disease management platforms that track diabetes and hypertension outcomes across diverse community populations.
Colorado, Arizona, and Utah represent dynamic, high-growth interior Western markets fueled by substantial population influxes, expanding technology corridors, and proactive healthcare system modernizations. Colorado’s Front Range corridor, stretching from Fort Collins through Denver to Colorado Springs, represents a thriving medtech hub anchored by UCHealth, Centura Health, and Children’s Hospital Colorado. UCHealth’s Virtual Health Center serves as an industry benchmark for virtual hospital operations, utilizing centralized predictive telemetry algorithms to monitor thousands of inpatient beds and remote home-care patients simultaneously. Arizona, anchored by the Phoenix and Tucson metropolitan regions, features major healthcare institutions, including Banner Health, HonorHealth, and the Mayo Clinic campus in Phoenix. Arizona’s growing retiree population sustains steady demand for connected ambulatory cardiac telemetry, continuous glucose monitors, and smart orthopedic implants. Utah, supported by Intermountain Health in Salt Lake City, represents a national leader in clinical informatics and evidence-based medicine. Intermountain’s sophisticated clinical research infrastructure drives extensive procurement of connected medical devices that validate therapeutic outcomes and optimize hospital operational workflows. Nevada, Idaho, Montana, and Wyoming provide additional regional velocity, driven by decentralized rural healthcare networks deploying satellite and cellular-enabled telemetry to connect remote critical access clinics with regional tertiary trauma centers.
The commercial environment in the West is defined by high institutional expectations for open-API software interoperability, multi-platform mobile application design, and seamless integration with consumer wearable ecosystems. Western healthcare systems aggressively reject proprietary, locked-down hardware architectures that create data silos. Medtech manufacturers that prioritize open, standards-based Fast Healthcare Interoperability Resources data streaming, flexible cloud software-as-a-service licensing, and intuitive, user-friendly patient interfaces achieve superior commercial penetration rates across Western healthcare networks.
Midwest
The Midwest represents a mature, highly resilient, and clinically rigorous regional market, generating USD 11.55 billion in 2026, up from historical levels of USD 6.70 billion in 2023, USD 8.00 billion in 2024, and USD 9.60 billion in 2025. The Midwestern market is projected to reach USD 31.85 billion by 2032, expanding at an 18.42% CAGR from 2027 to 2032. The region’s commercial market is distinguished by the presence of premier, globally renowned academic healthcare institutions, massive non-profit integrated delivery networks, a deeply established medical device manufacturing industrial corridor, and balanced demand spanning high-acuity urban tertiary hospitals and extensive rural critical-access healthcare facilities.
Illinois and Ohio represent the primary economic and clinical volume engines within the Midwestern IoMT landscape. The Chicago metropolitan area encompasses one of the densest and most lucrative healthcare markets in the nation, featuring major healthcare systems such as Northwestern Medicine, Rush University System for Health, Advocate Health Care, and the University of Chicago Medicine. These urban academic institutions are major capital purchasers of enterprise patient monitoring platforms, smart infusion systems, and AI-enabled bedside diagnostic telemetry. Illinois also serves as the corporate headquarters for major healthcare and pharmaceutical conglomerates that invest heavily in connected combination drug-device products. Ohio boasts an exceptionally powerful healthcare delivery infrastructure, anchored by the globally celebrated Cleveland Clinic, OhioHealth, and The Ohio State University Wexner Medical Center. The Cleveland Clinic operates as a global pioneer in clinical device innovation and remote patient monitoring, maintaining advanced virtual care command centers that track cardiac telemetry and chronic disease parameters across regional and international patient populations. Ohio healthcare systems demonstrate aggressive procurement of connected clinical surveillance tools, smart hospital beds, and zero-trust medical device cybersecurity solutions.
Minnesota, Indiana, and Wisconsin provide substantial market depth, underpinned by the world-famous “Medical Alley” medtech innovation corridor in Minnesota and the extensive life sciences manufacturing infrastructure in Indiana. Minnesota hosts the preeminent Mayo Clinic in Rochester, universally recognized as a benchmark for clinical excellence, research, and healthcare technology deployment. The Mayo Clinic Center for Digital Health continuously evaluates and deploys prototype IoMT hardware, from AI-assisted wearable ECG patches to autonomous inpatient monitoring suites. Furthermore, Minnesota’s Medical Alley houses hundreds of medical device companies, providing an extraordinary concentration of clinical regulatory, engineering, and cybersecurity talent that drives regional market expansion. Indiana features major healthcare networks such as Indiana University Health and Franciscan Health, alongside significant pharmaceutical and medical device manufacturing operations in Indianapolis and Warsaw, the recognized orthopedic manufacturing capital of North America. Warsaw’s orthopedic device leaders are heavily driving the development and clinical adoption of smart orthopedic implants equipped with embedded range-of-motion and force telemetry sensors. Wisconsin, anchored by Advocate Aurora Health, Froedtert Health, and the University of Wisconsin Health in Madison, exhibits sustained investment in connected clinical workflows and remote monitoring platforms, bolstered by the presence of Epic Systems in Verona, the dominant electronic health record vendor in the United States, which directly influences national medical device interoperability standards.
Michigan, Missouri, Iowa, and the Plains States—including Kansas, Nebraska, and the Dakotas—represent critical acute care and extensive rural health territories. Michigan’s market, centered on Detroit, Ann Arbor, and Grand Rapids, is anchored by Corewell Health, Henry Ford Health, and Michigan Medicine. These systems demonstrate sustained capital procurement of connected intensive care telemetry, automated medication dispensing cabinets, and hospital asset tracking systems. Missouri features premier academic medicine corridors in St. Louis and Kansas City, led by BJC HealthCare and Saint Luke’s Health System, which aggressively deploy connected chronic disease platforms. Iowa, Kansas, and the Dakotas maintain expansive networks of rural critical access hospitals that rely heavily on centralized telehealth hubs and cellular-enabled remote patient monitoring kits to oversee diabetic and hypertensive patients residing hundreds of miles from specialized medical specialists.
Procurement behavior across the Midwest is characterized by methodical, evidence-driven clinical purchasing committees, an intense institutional focus on total cost of ownership, and a strong demand for verifiable, peer-reviewed clinical efficacy data. Midwestern healthcare executives and clinical department heads demand proof that connected medical devices deliver tangible reductions in 30-day readmissions, measurable improvements in nurse retention, and flawless integration with existing electronic medical records. Device vendors succeed in this region by providing transparent, long-term pricing models, rock-solid hardware reliability, and comprehensive clinical workflow consulting services.
Northeast
The Northeast represents a highly sophisticated, high-value, and clinically prestigious regional market, accounting for USD 8.50 billion in 2026, having grown from USD 5.10 billion in 2023, USD 6.00 billion in 2024, and USD 7.15 billion in 2025. The Northeastern market is projected to reach USD 22.80 billion by 2032, demonstrating a 17.88% CAGR from 2027 to 2032. While the Northeast is geographically more compact than the South or Midwest, it features the nation’s highest geographic density of elite academic medical centers, Ivy League teaching hospitals, specialized research institutes, and discerning healthcare systems operating with significant capital expenditure allocations.
New York represents the economic cornerstone of the Northeastern IoMT landscape, propelled by the extraordinary concentration of world-class healthcare systems across the New York City metropolitan area, Long Island, and Westchester County, complemented by extensive upstate practice networks. New York City hosts legendary medical institutions, including NewYork-Presbyterian Hospital, Mount Sinai Health System, NYU Langone Health, Memorial Sloan Kettering Cancer Center, and Montefiore Health System. These massive health networks operate with high patient caseloads and manage some of the most clinically complex, high-acuity patient populations in the nation. New York hospitals invest heavily in space-efficient, ceiling-mounted patient monitoring infrastructure, connected smart infusion pump fleets, and AI-enabled diagnostic imaging integration platforms. Furthermore, New York State has enacted stringent clinical cybersecurity mandates and strict registered nurse staffing ratio guidelines, compelling hospital administrators to aggressively procure connected vital signs automation devices and zero-trust IoMT cybersecurity software to safeguard clinical networks and maximize nursing efficiency.
Massachusetts represents the intellectual and biotechnological innovation nucleus of the Northeast, anchored by the world-renowned Boston-Cambridge life sciences ecosystem. The state boasts globally premier academic medical institutions, including Mass General Brigham (encompassing Massachusetts General Hospital and Brigham and Women’s Hospital), Beth Israel Lahey Health, Boston Children’s Hospital, and UMass Memorial Health. Mass General Brigham operates extensive digital health and artificial intelligence testing centers, serving as a primary global proving ground for connected medical hardware, clinical-grade biosensor patches, and predictive clinical software. The dense concentration of academic researchers, venture-backed digital health startups, and leading engineering institutions, such as the Massachusetts Institute of Technology and Harvard University, creates an ecosystem where next-generation IoMT prototypes transition rapidly from clinical research laboratories into commercial hospital deployments.
Pennsylvania, New Jersey, and Connecticut represent affluent, highly densely populated healthcare corridors characterized by mature health systems and expansive outpatient surgical networks. In Pennsylvania, healthcare delivery is anchored by the University of Pittsburgh Medical Center in the west and Penn Medicine, Jefferson Health, and Temple Health in the east. UPMC represents an internationally renowned integrated delivery and finance system that operates both healthcare facilities and health insurance plans, providing a unified economic incentive to aggressively deploy connected remote patient monitoring to lower total costs of care. Penn Medicine’s Center for Health Care Innovation leads national research into connected wearable adherence, automated patient messaging loops, and inpatient virtual surveillance platforms. New Jersey features a dense healthcare network, including Hackensack Meridian Health and RWJBarnabas Health, which invest heavily in connected medication management and ambulatory telemetry. Connecticut’s Gold Coast and Hartford regions, anchored by Yale New Haven Health and Hartford HealthCare, demonstrate high capital investment in connected surgical robotics, outpatient cardiology telemetry, and enterprise hospital asset tracking.
Maine, New Hampshire, Vermont, and Rhode Island complete the Northeastern landscape, representing stable healthcare markets with high proportions of aging rural populations, particularly across northern New England. Regional health networks, such as MaineHealth, Dartmouth Health in New Hampshire, and the University of Vermont Health Network, actively deploy connected remote physiological monitoring and cellular-enabled diagnostic tools to deliver chronic disease management across mountainous and coastal rural communities where geographic distance impedes regular physical clinic attendance.
Procurement across the Northeast is characterized by uncompromising scientific rigor, academic validation, and peer-reviewed clinical scrutiny. Healthcare purchasing decisions are heavily influenced by renowned physician-researchers and academic department chairs who demand robust evidence demonstrating clinical sensitivity, device measurement precision, and algorithmic transparency. Medtech vendors targeting the Northeast must deliver high-fidelity clinical engineering, impeccable regulatory clearance documentation, and seamless integration with complex hospital clinical research databases and picture archiving and communication systems.
Key Market Players
The competitive landscape of the U.S. Internet of Medical Things Market is defined by a strategic convergence of diversified global medical device conglomerates, specialized digital health innovators, ambulatory telemetry pioneers, and clinical diagnostic leaders.
Highly relevant players operating in the U.S. Internet of Medical Things industry include:
Medtronic plc
GE HealthCare Technologies Inc.
Abbott Laboratories
Baxter International Inc.
Boston Scientific Corporation
Philips Healthcare (Philips North America)
DexCom, Inc.
ResMed Inc.
Masimo Corporation
Stryker Corporation
Becton, Dickinson and Company (BD)
Siemens Healthineers USA
Honeywell Life Care Solutions
BioTelemetry, Inc. (A Philips Company)
Insulet Corporation
Medtronic plc represents one of the foremost global benchmarks in connected implantable and therapeutic medical devices, commanding an extensive market share across cardiac rhythm management, neuromodulation, diabetes management, and surgical navigation. Medtronic differentiates its connected hardware portfolio through the integration of proprietary telemetry systems, such as the CareLink network, which seamlessly connects implantable cardioverter-defibrillators, pacemakers, and insertable cardiac monitors to cloud-based clinical management portals. In diabetes, Medtronic’s MiniMed automated insulin delivery systems combine continuous subcutaneous insulin infusion with real-time interstitial sensor telemetry to create sophisticated closed-loop glycemic control platforms, providing clinicians with actionable therapeutic analytics and automated patient tracking.
GE HealthCare Technologies Inc. occupies a preeminent position across stationary acute-care patient monitoring, diagnostic imaging connectivity, and enterprise hospital operations software. The company’s CARESCAPE patient monitoring platform and Mural Virtual Care Solution aggregate multi-parameter physiological waveforms from bedside monitors, mechanical ventilators, and maternal-infant care devices across entire hospital networks. GE HealthCare leverages its Edison digital health platform to deploy artificial intelligence algorithms directly to edge acquisition hardware, enabling early detection of patient clinical deterioration and optimizing intensive care unit capacity management across leading academic and regional health systems throughout the United States.
Abbott Laboratories maintains a dominant commercial footprint spanning outpatient continuous glucose monitoring, connected cardiac rhythm management, and rapid point-of-care diagnostics. Abbott’s FreeStyle Libre continuous glucose monitoring ecosystem represents one of the most widely prescribed biosensing platforms in the nation, utilizing compact, factory-calibrated disposable sensors that stream real-time glycemic data directly to consumer smartphones and cloud-connected clinical portals. In cardiovascular care, Abbott’s Gallant family of connected pacemakers and implantable cardioverter-defibrillators incorporates direct Bluetooth wireless technology, linking patients to the secure Merlin.net patient care network to deliver continuous, remote cardiac rhythm surveillance without requiring manual patient intervention.
Baxter International Inc. represents an indispensable pillar of connected acute care, renal therapy, and hospital smart medication delivery. Following its strategic acquisition of Hillrom, Baxter unified intelligent hospital beds, patient contact-free monitoring arrays, and enterprise clinical communication platforms with its legacy volumetric infusion pump lines. Baxter’s connected portfolio includes the Spectrum IQ and Novum IQ smart infusion pump platforms, which utilize bidirectional wireless connectivity to integrate with hospital electronic medication administration records and auto-download institutional drug libraries. Baxter’s automated peritoneal dialysis systems, equipped with the Sharesource remote patient management platform, allow nephrologists to remotely track home dialysis therapy adherence and adjust prescription settings, substantially reducing outpatient clinic visits and hospitalizations.
Boston Scientific Corporation commands substantial market share in connected electrophysiology, cardiac rhythm management, interventional cardiology, and chronic pain neurostimulation. Boston Scientific’s LATITUDE NXT Patient Management System provides continuous remote surveillance for patients implanted with cardiac resynchronization therapy devices, defibrillators, and the EMBLEM subcutaneous implantable cardioverter-defibrillator. In neuromodulation, Boston Scientific’s connected spinal cord stimulation systems utilize Bluetooth telemetry to allow patients and clinicians to wirelessly program therapeutic stimulation frequencies and track pain relief outcomes, optimizing clinical therapy management for patients suffering from chronic intractable pain.
Philips Healthcare, operating through Philips North America, brings world-class medical electronics engineering to the critical care patient monitoring, enterprise telehealth, and home respiratory landscapes. Philips’ IntelliVue patient monitoring family represents an industry gold standard across hospital intensive care units and emergency departments, providing modular physiological parameter tracking, advanced arrhythmia detection algorithms, and automated data synchronization with hospital electronic health records. Through its connected care informatics platforms, Philips delivers comprehensive virtual care solutions, including tele-ICU command centers and eCareCoordinator portals that empower health systems to manage high-acuity inpatient beds and distributed chronic patient populations from centralized clinical hubs.
DexCom, Inc. is a recognized global pioneer and pure-play innovator dedicated exclusively to continuous glucose monitoring technology for individuals with diabetes. Dexcom’s flagship G6 and G7 continuous glucose monitoring systems feature ultra-miniaturized, fully disposable biosensors that measure subcutaneous glucose levels every five minutes and transmit data via encrypted Bluetooth Low Energy channels to smartphones, smartwatches, and companion automated insulin delivery pumps. Dexcom distinguishes itself through its open-API software architecture, partnering seamlessly with automated insulin pump manufacturers, digital insulin pen developers, and enterprise remote patient monitoring platforms to deliver comprehensive, real-time glycemic intelligence to patients and healthcare providers nationwide.
ResMed Inc. represents the global market leader in cloud-connected respiratory care hardware and digital health software for sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disorders. ResMed’s AirSense continuous positive airway pressure platforms and Astral mechanical ventilators feature factory-installed cellular modems that automatically stream daily therapy usage, mask leak rates, and apnea-hypopnea index scores to the proprietary AirView clinical management platform. By accumulating billions of nights of clinical respiratory telemetry, ResMed provides pulmonologists and home medical equipment providers with predictive analytics tools that identify therapy non-compliance, automate patient intervention workflows, and substantially improve long-term positive airway pressure adherence rates.
Masimo Corporation is a preeminent developer of non-invasive patient monitoring technologies, specialized optical biosensors, and connected hospital automation systems. Masimo’s SET measure-through motion and low-perfusion pulse oximetry technology represents the foundational clinical standard in thousands of U.S. hospital operating rooms and intensive care units. The company has aggressively expanded into the Internet of Medical Things through its Masimo SafetyNet and Root patient monitoring platforms, deploying wireless, wearable optical pulse oximetry sensors and multi-parameter biosensor patches that continuously transmit physiological telemetry to centralized hospital displays and home clinical management dashboards, enabling safe patient surveillance across acute-to-home transitions.
Stryker Corporation represents an engineering powerhouse across connected surgical suites, emergency medical services telemetry, and intelligent hospital infrastructure. Stryker’s iSuite digital operating room platforms integrate surgical visualization towers, endoscopic cameras, and surgical navigation tools into unified, cloud-connected interfaces that stream surgical telemetry and procedural records to hospital data networks. In emergency care, Stryker’s LIFEPAK monitor/defibrillator series and the CODE-STAT data review software allow emergency medical services teams to transmit pre-hospital 12-lead electrocardiograms and cardiopulmonary resuscitation quality metrics directly to hospital emergency departments in real time. Furthermore, Stryker’s ProCuity smart hospital bed series incorporates wireless load-cell scales and fall-prevention sensors that communicate directly with nurse call systems, mitigating inpatient fall events.
Becton, Dickinson and Company (BD) is an indispensable global leader in hospital medication management, clinical point-of-care diagnostics, and patient safety solutions. BD commands extensive installed bases across American health systems through its BD Alaris smart infusion system and BD Pyxis automated medication dispensing cabinets. BD’s connected medication management continuum integrates infusion pumps, dispensing cabinets, and pharmacy inventory systems with hospital electronic health records via enterprise wireless networks, ensuring closed-loop medication verification from pharmacy order formulation to bedside intravenous administration. BD’s continuous investment in Dose Error Reduction Systems and cybersecurity patching architectures safeguards health systems from preventable adverse drug events and clinical network disruptions.
Siemens Healthineers USA, the medical technology arm of Siemens, delivers advanced connectivity across clinical laboratory diagnostics, point-of-care hematology and urinalysis analyzers, and diagnostic medical imaging systems. Siemens Healthineers utilizes its smart remote services ecosystem and teamplay digital health platform to link thousands of distributed clinical diagnostic instruments to centralized hospital cloud networks. This connected architecture enables predictive maintenance monitoring, automated calibration tracking, and rapid transmission of point-of-care diagnostic test results directly to treating physician electronic health record portals, optimizing laboratory operational throughput and clinical diagnostic turnaround times.
Honeywell Life Care Solutions represents a major technology innovator specializing in enterprise remote patient monitoring, mobile clinical communication platforms, and telehealth software. Honeywell provides healthcare organizations with integrated remote health management kits combining cellular-connected tablets, multi-parameter biometric sensors, and the LifePath clinical software platform. Honeywell’s systems allow clinical care coordinators to monitor vital sign trends, administer interactive patient disease education modules, and conduct secure video consultations, delivering scalable, cost-effective chronic disease surveillance across Medicare Advantage and managed Medicaid patient cohorts.
BioTelemetry, Inc., operating as an integral subsidiary of Philips, represents one of the largest and most established remote cardiac monitoring service and technology providers in the United States. BioTelemetry provides an exhaustive ambulatory cardiac monitoring portfolio encompassing wireless mobile cardiac outpatient telemetry patches, continuous multi-day Holter monitors, and digital event recorders. BioTelemetry’s proprietary algorithm architecture continuously analyzes ambulatory electrocardiographic signals, automatically transmitting flagged arrhythmias over cellular networks to dedicated, 24/7/365 independent diagnostic testing facilities where certified cardiac technicians validate events and notify treating cardiologists, enabling rapid clinical intervention for life-threatening cardiac dysrhythmias.
Insulet Corporation is a high-growth medical device innovator that has revolutionized diabetes management through its Omnipod tubeless continuous insulin delivery system. Insulet’s Omnipod 5 automated insulin delivery platform features a wearable, waterproof, tubeless insulin pod that incorporates an automated glycemic control algorithm directly on the on-body device. The pod communicates wirelessly via Bluetooth Low Energy with integrated continuous glucose monitors, automatically adjusting insulin delivery every five minutes based on real-time glucose trends without requiring tubing or daily skin punctures. Insulet’s cloud-based Insulet Provided Glooko and proprietary data ecosystems allow patients and endocrinologists to review comprehensive insulin delivery and glycemic trends, establishing Insulet as a premier competitor in connected chronic metabolic therapeutics.
Recent Developments
The U.S. Internet of Medical Things industry has undergone profound corporate consolidation, technological acceleration, and federal regulatory transformation between 2024 and 2026.
A defining structural development has been the aggressive statutory enforcement of mandatory medical device cybersecurity regulations executed by the U.S. Food and Drug Administration under Section 524B of the Federal Food, Drug, and Cosmetic Act. Starting in 2024 and reaching full institutional enforcement by 2026, the FDA has systematically exercised its “Refuse to Accept” authority for new 510(k), De Novo, and Premarket Approval submissions that fail to meet comprehensive cybersecurity standards. Medical device manufacturers are now legally mandated to provide verified Software Bills of Materials disclosing all open-source and commercial software components, demonstrate end-to-end vulnerability tracking architectures, maintain verified postmarket vulnerability disclosure programs, and provide regular, coordinated security patch cadences. This regulatory posture has triggered widespread capital retirement of vulnerable, legacy medical device fleets across American hospitals, forcing health system procurement committees to prioritize cyber-hardened, zero-trust connected hardware.
Federal reimbursement policy for digital health and remote monitoring has experienced critical expansion and refinement under annual Centers for Medicare and Medicaid Services Physician Fee Schedule rulings. Throughout 2024, 2025, and 2026, CMS solidified and clarified the clinical utilization guidelines for Remote Physiological Monitoring Current Procedural Terminology codes 99453, 99454, 99457, and 99458, alongside Remote Therapeutic Monitoring codes 98975 through 98981. Crucially, CMS established clearer documentation standards for the minimum 16-day biometric data transmission requirement per 30-day billing cycle while introducing expanded payment provisions for multi-disciplinary clinical staff time and federally qualified health centers. These regulatory adjustments have catalyzed massive institutional investments by large physician practices, multi-specialty clinics, and health plans, establishing remote monitoring as a standardized, permanent standard of outpatient care for hypertension, chronic heart failure, and musculoskeletal rehabilitation.
Product innovation within artificial intelligence-driven edge biosensors achieved clinical commercialization between 2024 and 2026. Device manufacturers successfully gained FDA 510(k) clearances for ultra-low-power microchips that embed deep neural network algorithms directly onto wearable patch sensors. Rather than transmitting massive volumes of raw, unprocessed biometric waveforms over wireless networks—which rapidly depletes device batteries and consumes extensive network bandwidth—these edge-AI sensors process physiological signals locally on the patient’s body. The microchips filter out movement artifacts, assess physiological signal quality, and transmit only clinically relevant telemetry bursts and validated diagnostic anomaly flags directly to hospital command centers. This engineering leap has extended the continuous operational battery lifespan of disposable wearable biosensors from several days to over two weeks, dramatically lowering per-patient monitoring costs for post-surgical hospital-at-home programs.
The clinical integration of private 5G local area networks and network slicing architectures gained rapid commercial traction across major American academic medical campuses between 2024 and 2026. Leading telecommunications infrastructure providers and healthcare systems executed landmark commercial deployments of dedicated, on-premise 5G standalone networks across multi-hospital complexes in Texas, California, Massachusetts, and Ohio. Private 5G networks provide ultra-reliable low-latency communications with deterministic quality of service, enabling high-density medical telemetry environments where thousands of connected infusion pumps, patient monitors, surgical robots, and mobile clinician tablets operate simultaneously without the signal dropouts, latency spikes, or radiofrequency interference historically encountered on congested hospital enterprise Wi-Fi bands.
Corporate mergers, acquisitions, and strategic technology alliances have reshaped competitive positioning across connected diagnostics, chronic disease monitoring, and clinical workflow platforms. Established medical device conglomerates have aggressively acquired agile digital health startups, specialized IoMT cybersecurity platforms, and remote cardiac monitoring service networks to fortify their software portfolios and lock in multi-year hospital service contracts. Furthermore, global enterprise cloud computing giants entered into long-term strategic technology partnerships with premier medtech hardware manufacturers. These alliances focus on engineering native Fast Healthcare Interoperability Resources data pipelines that ingest continuous medical device telemetry directly into secure cloud data platforms, allowing healthcare systems to train proprietary clinical deterioration algorithms and automate electronic health record documentation workflows.
Inpatient virtual nursing infrastructure and non-contact continuous monitoring transformed from experimental pilot programs into standard hospital capital equipment deployments between 2024 and 2026. Driven by persistent national registered nurse staffing shortages and escalating labor costs, major health systems deployed thousands of hospital beds equipped with integrated under-mattress piezoelectric sensor arrays and optical camera surveillance suites. These non-contact sensor arrays continuously track respiratory rates, heart rates, and patient bed mobility without requiring skin leads or blood pressure cuffs. Coupled with centralized virtual nursing command centers where experienced remote nurses oversee dozens of patient rooms simultaneously via high-definition bidirectional video and real-time telemetry dashboards, this connected architecture has proven to significantly reduce patient fall incidents, accelerate emergency resuscitation response times, and alleviate severe cognitive burnout among bedside clinical nursing personnel.
Conclusion
The U.S. Internet of Medical Things Market is positioned to expand from USD 56.65 billion in 2026 to approximately USD 162.80 billion by 2032, supported by an aggressive 19.23% CAGR from 2027 to 2032. Historical market development from USD 31.85 billion in 2023, USD 38.40 billion in 2024, and USD 46.50 billion in 2025 demonstrates the structural resilience, non-cyclical clinical necessity, and rapid technological modernization of the connected medical device landscape across American healthcare.
The underlying growth thesis is propelled by irreversible demographic, economic, and operational transformations across the healthcare continuum. The dramatic expansion of the American geriatric population, paired with a massive clinical burden of multi-system chronic diseases including cardiovascular disorders, hypertension, diabetes, and respiratory conditions, renders episodic, hospital-centric care economically unsustainable. Managing these expanding patient cohorts requires continuous, proactive biometric surveillance delivered through clinical-grade connected hardware that prevents catastrophic clinical decompensation, lowers acute hospital readmissions, and safeguards hospital margins under federal value-based reimbursement frameworks.
The commercial marketplace is defined by the rapid migration away from isolated, analog medical devices toward intelligent, cloud-integrated clinical ecosystems. Modern healthcare providers and integrated delivery networks refuse to procure standalone hardware that operates within proprietary data silos. Clinical organizations demand medical devices that incorporate native Fast Healthcare Interoperability Resources software integration, embedded edge artificial intelligence capable of filtering biometric noise and mitigating alarm fatigue, and verified, zero-trust hardware cybersecurity architectures that comply with stringent federal statutory mandates under Section 524B of the FD&C Act.
Smart wearable biosensors and remote physiological monitoring hardware will maintain their position as the premier volume and growth drivers, propelled by the nationwide expansion of continuous glucose monitoring across diverse diabetes populations and the standard-of-care adoption of multi-parameter adhesive patch biosensors across decentralized hospital-at-home care models. Simultaneously, acute-care stationary monitoring platforms, smart dose-error-reduction infusion systems, connected implantable cardiac telemetry, and pre-hospital emergency medical telemetry will capture substantial value through high-velocity recurring software subscriptions, consumable sensor replenishments, and managed connectivity services.
Geographically, the South will maintain absolute market revenue leadership, propelled by dense population concentrations, nation-leading chronic disease prevalence, and corporate hospital networks executing enterprise-wide connected device standardizations across Texas, Florida, and Tennessee. The West will lead the nation in technological growth velocity, driven by California’s venture capital and medtech innovation corridors, progressive digital health policies, and tech-forward healthcare systems setting national benchmarks for cloud-native medical IoT deployment. The Midwest will continue to provide a deeply resilient foundation of capital equipment procurement across globally renowned academic hospital complexes and extensive rural critical-access networks. The Northeast will remain the country’s most scientifically rigorous and clinically prestigious regional market, distinguished by elite academic teaching institutions and premier medical centers that establish evidence-based standards for connected health technologies.
For medical device manufacturers, enterprise software providers, health systems, and healthcare institutional investors, competitive advantage through 2032 will belong to organizations that master end-to-end clinical workflow integration. Superior sensor engineering alone is no longer sufficient to secure sustainable market leadership. Winning enterprises will successfully combine clinical-grade biometric accuracy with zero-trust hardware cybersecurity, frictionless cellular connectivity, native electronic health record data liquidity, and predictive edge artificial intelligence that converts continuous physiological data streams into timely, actionable, and life-saving clinical interventions across the entire continuum of American healthcare.